A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic ...

AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with ...

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Enhertu is an antibody drug conjugate (ADC) that was discovered by Daiichi Sankyo and is being further developed and commercialized under a partnership with AstraZeneca. The antibody component of ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their antibody drug conjugate ...